< Browse more articles

Ontario’s Workplace Safety and Insurance Board (WSIB) has introduced a new policy with respect to medical cannabis that took effect on March 1, 2019.

The new medical cannabis policy applies to all purchases of medical cannabis and vapourizers made on, or after March 1, 2019, for all accident dates.

The policy, which provides a framework for entitlement to, and approval of, medical cannabis by the WSIB, sets out the following five conditions for entitlement:

  • Neuropathic pain;
  • Spasticity resulting from a spinal cord injury;
  • Chemotherapy-induced nausea and vomiting;
  • Loss of appetite associated with HIV or AIDS; and
  • Pain and other symptoms in palliative care.

In addition to these conditions, there are several factors that must be met before the WSIB will consider entitlement to medical cannabis, including:

  • the worker has previously tried conventional treatments for their condition;
  • the worker has received a clinical assessment for medical cannabis treatment;
  • the benefits of medical cannabis treatment outweigh the risks;
  • the treating health-care professional has authorized medical cannabis for the employee.

For more information, HRAI recommends you visit the WSIB website.